Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWCTZ7)

Drug Name

Decynium 22 Drug Info

Synonyms

Pseudoisocyanine; 1,1'-Diethyl-2,2'-cyanine; 1-Ethyl-2-((1-ethyl-2(1H)-quinolylidene)methyl)quinolinium; 20766-49-8; CHEMBL1197556; CHEBI:37994; Pseudocyanine; 1-ethyl-2-[(E)-(1-ethylquinolin-2(1H)-ylidene)methyl]quinolinium; Diethylpseudoisocyanine; MLS000532635; AC1NUNMU; AC1Q1IYW; SMR000137574; AC1L2OT9; CBDivE_000769; SCHEMBL737002; 977-96-8 (iodide); 2402-42-8 (chloride); SCHEMBL13619260; 1613-31-6 (bromide); BDBM39687; cid_5717105; CHEBI:38002; DTXSID40174835; MolPort-006-385-585; STK396423; (E)-1,1'-diethyl-2,2'-cyanine; Dy22; 1,1'-diethyl-2,2'-cyanine; NSC-97374

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2]

Cross-matching ID

PubChem CID: 5484462
ChEBI ID: CHEBI:37993
CAS Number: CAS 977-96-8
TTD Drug ID: DMWCTZ7
VARIDT Drug ID: DR00630

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Quinone reductase 2 (NQO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melatonin	DMKWFBT	Insomnia	7A00-7A0Z	Approved	[4]
NSC-645809	DMPJQZG	Breast cancer	2C60-2C65	Phase 2	[5]
Prolarix	DMZIQ8G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
CB1954	DMVP4YK	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[7]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[7]
2-iodo-melatonin	DMSEIUP	Discovery agent	N.A.	Investigative	[8]
3,4,5-Trimethoxy-4'-amino-trans-stilbene	DMDBOJ5	Discovery agent	N.A.	Investigative	[9]
NSC-645808	DMMBAR3	Discovery agent	N.A.	Investigative	[5]
NSC-106080	DMR6P9S	Discovery agent	N.A.	Investigative	[2]
NSC-99528	DMXZAIG	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Quinone reductase 2 (NQO2)	TTJLP0R	NQO2_HUMAN	Inhibitor	[2]
Solute carrier family 29 member 4 (SLC29A4)	TTTR957	S29A4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13.
2	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
3	Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol. 2005 Nov;68(5):1397-407.
4	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
5	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
6	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
9	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66.